家族性阿尔茨海默病早期行为变化:结果主要继承了老年痴呆症网络(S24.005)

文摘

摘要目的:描述早期行为家族性阿尔茨海默氏症(时尚)的变化。

背景:AD病理开始出现明显症状之前15到20年。之前的研究表明焦虑和抑郁等精神症状的早期迹象或广告发展的危险因素。人在50%继承时尚突变的风险让我们识别早期的行为变化。

设计/方法:中的第一个212受试者中主导性继承了网络,老年痴呆症的研究人员对时尚或50%的风险,评价与神经精神Inventory-Q (NPI-Q)的15个老年抑郁量表(GDS)和临床痴呆评定量表(CDR)。无症状(CDR = 0),轻度症状(0.5),和明显影响(CDR > 0)时尚突变携带者(MCs)相比,非承运人(nc)对行为变化的频率NPI-Q(卡方检验)和抑郁严重程度在GDS(双面t检验)。

结果:nc 133受试者MCs - 79。在MCs 75 CDR得分为0,37得分0.5,和21分数> 0.5。没有无症状差异MCs和nc在神经精神症状。MCs CDR得分为0.5,有一个更高频率的风潮(30%比4%),冷漠(41%比3%),食欲的变化(30%比9%),抑郁症状(49%比15%),去抑制(16%比1%),易怒(51%比10%),和睡眠变化比nc(32%比4%)。意思是GDS分数升高轻度症状MCs(3.7和1.1)。在精神错乱的MCs,大多数行为症状的频率和平均GDS分数高于nc。

结论:健壮的行为变化在时尚发生前症状并不常见。增加搅拌,冷漠,去抑制、易怒、睡眠行为和抑郁可以伴随早期认知的变化。这些发现符合观察迟发性的广告。

支持:数据收集和共享这个项目得到了继承居多的老年痴呆症网络(滇、U01AG032438)由国家老龄问题研究所资助(NIA)。进一步支持这项工作来自加州大学洛杉矶分校阿尔茨海默病研究中心授予P50 ag - 16570,加州大学洛杉矶分校临床转化研究所1 ul1-rr033176,伊斯顿财团为阿尔茨海默病药物发现和生物标志物的发展。

披露:拳击手博士已经收到个人活动与武田制药和干细胞的补偿,公司作为一个顾问委员会成员。从詹森赌客已收到博士研究支持,辉瑞公司,Accera,百时美施贵宝,Inc .,惠氏制药公司。梁博士没有披露。弗洛勒斯博士没有披露。沃顿商学院博士没有披露。Goate博士没有披露。斯科菲尔德博士没有披露。凯恩斯博士没有披露。Benzinger博士已经收到个人补偿活动与礼来公司作为一个顾问委员会的参与者。Benzinger博士接到Avid Radiopharmaceuticals研究支持。 Dr. Fagan has nothing to disclose. Dr. Xiong has nothing to disclose. Dr. Ghetti has received personal compensation for activities with Bayer Pharmaceuticals Corporation. Dr. Ghetti has received research support from the NIA. Dr. McDade has nothing to disclose. Dr. Masters has nothing to disclose. Dr. Mayeux has nothing to disclose. Dr. Rossor has nothing to disclose. Dr. Sperling has received personal compensation for activities with Bayer, Bristol-Myers Squibb Company, Biogen Idec, Eisai, Inc., Elan Corporation, Eli Lilly & Company, Janssen, Pfizer Inc, and Roce. Dr. Sperling has received research support from Bristol-Myers Squibb Company. Dr. Salloway has received personal compensation from Elan, Sanofi-Aventis, Pfizer, Eisai, and Bristol-Myers Squibb. Honoraria from Eisai Inc., Pfizer Inc, Novartis, Forest, Elan, and Athena Diagnostics Data monito. Dr Salloway has received personal compensation in an editorial capacity for serving as Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences. Dr. Salloway has received research support from Elan, Wyeth, Janssen, Bristol-Myers Squibb, Eisai, Pfizer, Medivation, Myriad, GlaxoSmithKline, Neurochem, Cephalon, Forest, and Voyager; Alzheimer Disease Neuroimaging Initiative, Dominantly Inher. Dr. Marcus has nothing to disclose. Dr. Martins has nothing to disclose. Dr. Bateman has received personal compensation for activities with Link Medicine, JAI, Bristol-Myers Squibb Company, Pfizer Inc, Merck, SPRI, Elan Corporation, Eisai Inc., and Medtronic, Inc. Dr. Bateman has received royalty payments from Washington University. Dr. Bateman has received research support from AstraZeneca Pharmaceuticals and Merck & Co., Inc. Dr. Morris has received personal compensation for activities with Esteve Company, Eisai Inc., Janssen, GlaxoSmithKline, Inc., Novartis, Otsuka, and Pfizer Inc. Dr. Morris has received personal compensation in an editorial capacity for Medlink. Dr. Morris has received research support from Janssen, Eli Lilly & Company, and Pfizer, Inc.